3-(N-环丙基氨基磺酰基)苯甲酸 | 852933-50-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(N-环丙基氨基磺酰基)苯甲酸
• 中文别名: 3-[(环丙基氨基)磺酰基]苯甲酸
• 英文名称: 3-(N-cyclopropylsulfamoyl)benzoic acid
• 英文别名: 3-(N-cyclopropylaminosulfonyl)benzoic acid；3-[(cyclopropylamino)sulfonyl]benzoic acid；3-(cyclopropylsulfamoyl)benzoic Acid
• CAS: 852933-50-7
• 化学式: C₁₀H₁₁NO₄S
• mdl: MFCD06655562
• 分子量: 241.268
• InChiKey: KBRLADOVWCDAEI-UHFFFAOYSA-N

物化性质

• 沸点：
  465.9±47.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Cyclopropylsulfamoyl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Cyclopropylsulfamoyl)benzoic acid
CAS number: 852933-50-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11NO4S
Molecular weight: 241.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(N-环丙基氨基磺酰基)苯甲酸 在 硫酸 sodium tetrahydroborate 、 三溴化磷 、 sodium hydride 作用下， 以 四氢呋喃 、 四氯化碳 为溶剂， 反应 4.5h， 生成 3-(3-aminosulfonylbenzyl)-7-hydroxy-4-methyl-6-chloro-2-oxa-2H-1-benzopyran
  参考文献：
  名称：

  [EN] COUMARIN DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  [FR] DÉRIVÉ DE COUMARINE, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES

  摘要：

  本发明涉及一种具有如下式（I）的香豆素衍生物：其中X、Y1、Y2、Y3、R1、R2、R3和R4如本文所定义，或其药学上可接受的盐或溶剂。本发明还涉及包括本发明化合物的药物组合物，以及在治疗肿瘤和/或炎症中使用本发明化合物。

  公开号：

  WO2012171488A1
• 作为产物：
  描述：

  3-氯磺酰基苯甲酸 、 环丙胺 在 三乙胺 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 以55%的产率得到3-(N-环丙基氨基磺酰基)苯甲酸
  参考文献：
  名称：

  [EN] COUMARIN DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  [FR] DÉRIVÉ DE COUMARINE, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES

  摘要：

  本发明涉及一种具有如下式（I）的香豆素衍生物：其中X、Y1、Y2、Y3、R1、R2、R3和R4如本文所定义，或其药学上可接受的盐或溶剂。本发明还涉及包括本发明化合物的药物组合物，以及在治疗肿瘤和/或炎症中使用本发明化合物。

  公开号：

  WO2012171488A1

文献信息

• [EN] COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED<br/>[FR] COMPOSÉS, DESTINÉS PLUS PARTICULIÈREMENT À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE MALADIE OU D'UNE PATHOLOGIE POUR LAQUELLE UN INHIBITEUR DU BROMODOMAINE EST INDIQUÉ
  申请人：UNIV ZUERICH

  公开号：WO2016001452A1

  公开（公告）日：2016-01-07

  The invention relates to a compound for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated characterized by a general formula (1) and a compound according to formula (3).

  该发明涉及一种化合物，用于治疗溴结构域抑制剂指示的疾病或症状，其具有一般式（1）和根据式（3）的化合物。
• Substituted Quinazolones as Anti-Cancer Agents
  申请人：Aquila Brian

  公开号：US20080275022A1

  公开（公告）日：2008-11-06

  The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  本发明涉及化学式（I）的化合物或其药学上可接受的盐，其具有B-Raf抑制活性，因此在抗癌活性和人或动物体的治疗方法中有用。本发明还涉及制造所述化学化合物的方法，包含它们的制药组合物以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS
  申请人：Aquila Brian

  公开号：US20090118261A1

  公开（公告）日：2009-05-07

  The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  本发明涉及化学式(I)的化合物或其药学上可接受的盐，其具有B Raf抑制活性，因此对其抗癌活性有用，并且在人体或动物体的治疗方法中使用。本发明还涉及制造上述化学化合物的方法，包含它们的制药组合物以及在制造用于在温血动物（如人）中产生抗癌效果的药物中使用它们的用途。
• Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell
  作者：Yuqing Jia、Merve Oyken、Robbert Q. Kim、Rayman T.N. Tjokrodirijo、Arnoud H. de Ru、Antonius P. A. Janssen、Stephan M. Hacker、Peter A. van Veelen、Paul P. Geurink、Aysegul Sapmaz

  DOI：10.1021/acs.jmedchem.3c02410

  日期：2024.5.23

  integration of diverse chemical tools like small-molecule inhibitors, activity-based probes (ABPs), and proteolysis targeting chimeras (PROTACs) advances clinical drug discovery and facilitates the exploration of various biological facets of targeted proteins. Here, we report the development of such a chemical toolbox for the human Parkinson disease protein 7 (PARK7/DJ-1) implicated in Parkinson’s disease

  小分子抑制剂、基于活性的探针 (ABP) 和蛋白水解靶向嵌合体 (PROTAC) 等多种化学工具的集成推进了临床药物发现，并促进了对靶向蛋白质的各个生物学方面的探索。在此，我们报告了针对与帕金森病和癌症有关的人类帕金森病蛋白 7 (PARK7/DJ-1) 开发的化学工具箱。通过结合结构指导设计、小型化文库合成和高通量筛选，我们鉴定了两种有效的化合物JYQ-164和JYQ-173 ，通过共价和选择性地靶向其关键残基 Cys106，在体外和细胞内抑制 PARK7。利用JYQ-173 ，我们进一步开发了一种可渗透细胞的 Bodipy 探针JYQ-196 ，用于在活细胞中共价标记 PARK7，以及一流的 PARK7 降解剂JYQ-194 ，可选择性诱导其在人类细胞中的蛋白酶体降解。我们的研究提供了一个有价值的工具箱，以增强对细胞环境中 PARK7 生物学的理解，并为治疗干预开辟了新的机会。
• Synthesis and biological evaluation of novel (E)-N′-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors
  作者：Yang Zhou、Yan Li、Wen-Jing Wang、Pu Xiang、Xin-Mei Luo、Li Yang、Sheng-Yong Yang、Ying-Lan Zhao

  DOI：10.1016/j.bmcl.2015.06.054

  日期：2016.9

  Lysine specific demethylase 1 (LSD1) plays an important role in regulating histone lysine methylation at residues K4 and K9 on histone H3 and is recognized as an attractive therapeutic target in multiple malignancies. In this study, a series of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides were synthesized and biologically evaluated for their potential LSD1 inhibitory effect. Among them, compounds 5a and 5n showed the most potent LSD1 inhibitory activity with IC50 values of 1.4 and 1.7 nM, respectively, which were about 10 times more potent compared with (E)-N-(1-(5-chloro-2-hydroxyphenyl) ethylidene)-3-(morpholinosulf-only) benzohydrazide (J. Med. Chem. 2013, 56, 9496-9508; as reference compound). Compounds 5a and 5n also exhibited marked anti-proliferation activities against cancer cell lines that highly expressed LSD1. These results suggest that these optimized compounds might be served as promising LSD1 inhibitors against cancer, which merit further study. (C) 2016 Published by Elsevier Ltd.